Phase III Data For La Jolla's Angiotensin II Drug Leave Questions About Clinical Benefit
Executive Summary
La Jolla's LJPC-501 meets primary blood pressure endpoint in the Phase III ATHOS-3 vasodilatory shock trial, but data suggest benefits may not translate into clinically meaningful improvements.
You may also be interested in...
Finance Watch: Despite Bad News, IPOs And Public Offerings Keep Flowing
Solid Biosciences was able to launch an IPO earlier this year despite a last minute disclosure about a partial clinical hold, which is now a full clinical hold that's cost investors money. Even so, Arcus Biosciences was able to launch its IPO. Ideaya, JW lead recent VC financings.
FDA Bests Annual Novel Drug Approval Record With Four Oks In One Week
The agency's Dec. 21 approval of Giapreza became novel drug No. 46 of 2017, topping the 2015 mark of 45.
Survival Benefit For Hypotension Shock Drug Nice But Not Needed By FDA, La Jolla Says
La Jolla Pharmaceutical's angiotensin II drug LJPC-501 is on track for NDA via SPA this year, after meeting blood pressure increase primary endpoint in ATHOS-3, but also showing a trend toward an overall survival benefit.